Literature DB >> 28740645

Immunosuppression after lung transplantation: the search for the holy grail continues.

Stefan Schwarz1, Peter Jaksch1, Walter Klepetko1, Konrad Hoetzenecker1.   

Abstract

Year:  2017        PMID： 28740645      PMCID： PMC5506122          DOI： 10.21037/jtd.2017.04.66

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  13 in total

1.  Everolimus versus azathioprine in maintenance lung transplant recipients: an international, randomized, double-blind clinical trial.

Authors:  G I Snell; V G Valentine; P Vitulo; A R Glanville; D C McGiffin; J E Loyd; A Roman; R Aris; A Sole; A Hmissi; U Pirron
Journal:  Am J Transplant       Date:  2006-01       Impact factor: 8.086

2.  Everolimus Versus Mycophenolate Mofetil De Novo After Lung Transplantation: A Prospective, Randomized, Open-Label Trial.

Authors:  M Strueber; G Warnecke; J Fuge; A R Simon; R Zhang; T Welte; A Haverich; J Gottlieb
Journal:  Am J Transplant       Date:  2016-06-15       Impact factor: 8.086

Review 3.  De novo thrombotic microangiopathy after non-renal solid organ transplantation.

Authors:  Annelies Verbiest; Jacques Pirenne; Daan Dierickx
Journal:  Blood Rev       Date:  2014-09-20       Impact factor: 8.250

4.  Thrombotic microangiopathy associated with tacrolimus in lung transplantation.

Authors:  Juan Pablo Reig Mezquida; Amparo Solé Jover; Emilio Ansótegui Barrera; Juan Escrivá Peiró; Maria Desamparados Pastor Colom; Juan Pastor Guillem
Journal:  Arch Bronconeumol       Date:  2014-08-17       Impact factor: 4.872

5.  A retrospective 12-month study of conversion to everolimus in lung transplant recipients.

Authors:  A Roman; P Ussetti; F Zurbano; J M Borro; A Solé; M C Carreño; F Santos
Journal:  Transplant Proc       Date:  2011-09       Impact factor: 1.066

6.  Three-year results of an investigator-driven multicenter, international, randomized open-label de novo trial to prevent BOS after lung transplantation.

Authors:  Allan R Glanville; Christina Aboyoun; Walter Klepetko; Hermann Reichenspurner; Hendrik Treede; Erik A Verschuuren; Annette Boehler; Christian Benden; Peter Hopkins; Paul A Corris
Journal:  J Heart Lung Transplant       Date:  2014-06-16       Impact factor: 10.247

7.  Five-year outcomes with alemtuzumab induction after lung transplantation.

Authors:  Susan Shyu; Mary Amanda Dew; Joseph M Pilewski; Annette J DeVito Dabbs; Diana B Zaldonis; Sean M Studer; Maria M Crespo; Yoshiya Toyoda; Christian A Bermudez; Kenneth R McCurry
Journal:  J Heart Lung Transplant       Date:  2011-03-21       Impact factor: 10.247

8.  Alemtuzumab in lung transplantation: an open-label, randomized, prospective single center study.

Authors:  P Jaksch; J Ankersmit; A Scheed; A Kocher; G Muraközy; W Klepetko; G Lang
Journal:  Am J Transplant       Date:  2014-07-10       Impact factor: 8.086

9.  Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation.

Authors:  Andrea Azzola; Adrian Havryk; Prashant Chhajed; Katrin Hostettler; Judith Black; Peter Johnson; Michael Roth; Allan Glanville; Michael Tamm
Journal:  Transplantation       Date:  2004-01-27       Impact factor: 4.939

10.  Renal function preservation with the mTOR inhibitor, Everolimus, after lung transplant.

Authors:  Sonia Schneer; Mordechai R Kramer; Benjamin Fox; Viktoria Rusanov; Oren Fruchter; Dror Rosengarten; Ilana Bakal; Benjamin Medalion; Yael Raviv
Journal:  Clin Transplant       Date:  2014-04-16       Impact factor: 2.863
View more
  2 in total

1.  Immunosuppression for Lung Transplantation: Current and Future.

Authors:  Satish Chandrashekaran; Stacy A Crow Pharm; Sadia Z Shah; Chris J Arendt Pharm; Cassie C Kennedy
Journal:  Curr Transplant Rep       Date:  2018-07-13

2.  The Impact of New Treatments on Short- and MID-Term Outcomes in Bilateral Lung Transplant: A Propensity Score Study.

Authors:  Annalisa Boscolo; Andrea Dell'Amore; Tommaso Pettenuzzo; Nicolò Sella; Alessandro De Cassai; Elisa Pistollato; Nicola Cacco; Andrea Manzan; Agnese De Carolis; Federico Geraldini; Giulia Lorenzoni; Federica Pezzuto; Giovanni Zambello; Marco Schiavon; Fiorella Calabrese; Dario Gregori; Emanuele Cozzi; Federico Rea; Paolo Navalesi
Journal:  J Clin Med       Date:  2022-10-03       Impact factor: 4.964
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.